Should We Screen for Hereditary Hemochromatosis in Healthy Lebanese: a Pilot Study

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2011 May 10

PMID 21553046

Authors

Rami A R Mahfouz

Doja S Sarieddine

Khalil M Charafeddine

Rabab N Abdul Khalik

Najwa K Cortas

Rose T Daher

Affiliations

Soon will be listed here.

Abstract

Hereditary hemochromatosis (HHC) is a genetic disorder of iron metabolism characterized by abnormal accumulation of iron that may lead to organ damage and death. Diagnosis is usually based on various genetic and phenotypic criteria. The study goals were to perform mutation analysis for 18 different mutations associated with HHC in healthy Lebanese, determine their allele frequency, and compare iron-overload status in identified carriers versus those found to be wild-type for mutations analyzed. 116 healthy adults (59 males and 57 females) underwent DNA testing for 18 different HHC mutations, and biochemical testing for percent transferrin saturation (%TS) and ferritin. C282Y mutation was not detected. Only H63D mutation (rs1799945) was found with an overall carrier frequency of 25.8% (24.1% heterozygous and 1.7% homozygous). %TS and ferritin differed significantly between genders. %TS and ferritin were significantly higher in males with H63D mutation when compared to males with wild-type (P=0.001, 0.019; respectively); but not in females. The proportion of subjects with increased %TS and serum ferritin was not statistically different between those with H63D mutation and the wild-type in either gender. In addition, none of the subjects had concurrent increase in %TS and ferritin. In conclusion, the H63D carrier frequency in healthy Lebanese is comparable to other populations in the region, and it does not result in significant biochemical iron overload. Moreover, in the absence of the C282Y mutation, genetic screening for HHC is not recommended according to this preliminary study in healthy Lebanese.

References

Papazoglou D, Exiara T, Speletas M, Panagopoulos I, Maltezos E . Prevalence of hemochromatosis gene (HFE) mutations in Greece. Acta Haematol. 2003; 109(3):137-40. DOI: 10.1159/000069289. View

Feder J, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy D, Basava A . A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996; 13(4):399-408. DOI: 10.1038/ng0896-399. View

Barut G, Balci H, Bozdayi M, Hatemi I, Ozcelik D, Senturk H . Screening for iron overload in the Turkish population. Dig Dis. 2003; 21(3):279-85. DOI: 10.1159/000073985. View

Edison E, Bajel A, Chandy M . Iron homeostasis: new players, newer insights. Eur J Haematol. 2008; 81(6):411-24. DOI: 10.1111/j.1600-0609.2008.01143.x. View

Allen K, Bertalli N, Osborne N, Constantine C, Delatycki M, Nisselle A . HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis. Hepatology. 2010; 52(3):925-33. PMC: 2932765. DOI: 10.1002/hep.23786. View

McLaren C, Li K, McLaren G, Gordeuk V, Snively B, Reboussin D . Mixture models of serum iron measures in population screening for hemochromatosis and iron overload. Transl Res. 2006; 148(4):196-206. DOI: 10.1016/j.trsl.2006.05.006. View

Brandhagen D, Fairbanks V, Baldus W . Recognition and management of hereditary hemochromatosis. Am Fam Physician. 2002; 65(5):853-60. View

Gurrin L, Osborne N, Constantine C, McLaren C, English D, Gertig D . The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology. 2008; 135(6):1945-52. DOI: 10.1053/j.gastro.2008.08.056. View

Yonal O, Hatirnaz O, Akyuz F, Koroglu G, Ozbek U, Cefle K . Definition of C282Y mutation in a hereditary hemochromatosis family from Turkey. Turk J Gastroenterol. 2007; 18(1):53-7. View

10.

Neghina A, Anghel A . Hemochromatosis genotypes and risk of iron overload--a meta-analysis. Ann Epidemiol. 2010; 21(1):1-14. DOI: 10.1016/j.annepidem.2010.05.013. View

11.

Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T . Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood. 2000; 96(1):76-9. View

12.

Hanson E, Imperatore G, Burke W . HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol. 2001; 154(3):193-206. DOI: 10.1093/aje/154.3.193. View

13.

Alexander J, Kowdley K . HFE-associated hereditary hemochromatosis. Genet Med. 2009; 11(5):307-13. DOI: 10.1097/GIM.0b013e31819d30f2. View

14.

Alkhateeb A, Uzrail A, Bodoor K . Frequency of the hemochromatosis gene (HFE) variants in a Jordanian Arab population and in diabetics from the same region. Dis Markers. 2009; 27(1):17-22. PMC: 3834672. DOI: 10.3233/DMA-2009-0642. View

15.

LYON E, Frank E . Hereditary hemochromatosis since discovery of the HFE gene. Clin Chem. 2001; 47(7):1147-56. View

16.

Simsek H, Balaban Y, Yilmaz E, Sumer H, Buyukasik Y, Cengiz C . Mutations of the HFE gene among Turkish hereditary hemochromatosis patients. Ann Hematol. 2005; 84(10):646-9. DOI: 10.1007/s00277-005-1048-y. View

17.

Waalen J, Felitti V, Gelbart T, Beutler E . Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood. 2007; 111(7):3373-6. PMC: 2275006. DOI: 10.1182/blood-2007-07-102673. View

18.

Gurrin L, Bertalli N, Dalton G, Osborne N, Constantine C, McLaren C . HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology. 2009; 50(1):94-101. PMC: 3763940. DOI: 10.1002/hep.22972. View

19.

Griffiths W . Review article: the genetic basis of haemochromatosis. Aliment Pharmacol Ther. 2007; 26(3):331-42. DOI: 10.1111/j.1365-2036.2007.03387.x. View

20.

Whitlock E, Garlitz B, Harris E, Beil T, Smith P . Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2006; 145(3):209-23. DOI: 10.7326/0003-4819-145-3-200608010-00009. View